Archive · 16 Jun 2025
Lupin Partners with Sino Universal Pharma to Expand in China
Lupin, a big medicine maker, is teaming up with a Chinese company to sell a lung medicine called Tiotropium in China.
Lupin will make the medicine, and the Chinese company will get it approved for sale.
This medicine helps people breathe easier.
Lupin has been working with Chinese companies since 2022 and is growing its business there.
They are choosing to work with local partners instead of setting up their own company to help them sell their products in China.
Lupin, a pharmaceutical company, has signed a license and supply agreement with Sino Universal Pharmaceuticals in China.
The agreement allows Lupin to sell Tiotropium Dry Powder Inhaler (DPI) in the Chinese market.
Sino Universal Pharmaceuticals will handle regulatory approval, while Lupin will manufacture the medicine.
Lupin entered the Chinese market in 2022 through partnerships with Shenzhen Foncoo Pharmaceutical and Yabao Pharmaceutical.
Lupin focuses on high-demand specialty medicines and uses non-equity partnerships to navigate the Chinese market.
- Who
- Lupin and Sino Universal Pharmaceuticals.
- What
- Lupin signed an agreement to sell lung medicine in China.
- When
- Lupin entered the Chinese market in January 2022.
- Where
- China.
- Why
- To expand business in China and provide access to healthcare solutions.
- Company
- Lupin
- Partner
- Sino Universal Pharmaceuticals
- Medicine
- Tiotropium Dry Powder Inhaler (DPI)
- Market
- China
- Lupin's Market Cap
- Rs 91000 crore